Suppr超能文献

mRNA COVID-19 疫苗接种后迟发性全身性荨麻疹反应。

Delayed systemic urticarial reactions following mRNA COVID-19 vaccination.

机构信息

From the Division of Allergic Diseases, Mayo Clinic, Rochester, Minnesota; and.

Division of Pulmonary, Allergy, and Sleep Medicine, Mayo Clinic, Jacksonville, Florida.

出版信息

Allergy Asthma Proc. 2022 Jan 1;43(1):40-43. doi: 10.2500/aap.2022.43.210101.

Abstract

As the vaccination campaign in response to the coronavirus disease 2019 (COVID-19) pandemic continues, concerns with regard to adverse reactions to the vaccine remain. Although immediate hypersensitivity reactions have received much attention, delayed systemic urticarial reactions after vaccination can occur. To describe the clinical presentation, vaccine excipient skin testing results, and outcomes of subsequent COVID-19 vaccination in patients who experienced delayed systemic urticarial reactions after messenger RNA (mRNA) COVID-19 vaccination. This was a retrospective case series of 12 patients referred to the Mayo Clinics in Rochester, Minnesota, and Jacksonville, Florida, between January 19, 2021, and April 30, 2021, for evaluation of delayed systemic urticarial reactions after mRNA COVID-19 vaccination. Demographics, medical and allergic history, reaction details, vaccine excipient skin testing results (when performed), and the outcome after subsequent vaccination were collected for each patient. The mean age of the patients was 52 years, all were white, and 9 (75%) were women. Half of the patients had a history of drug allergy, and one had a history of chronic spontaneous urticaria. Seven patients reacted to the Pfizer-BioNTech vaccine and five reacted to the Moderna vaccine. Seven patients developed symptoms between 8 and 24 hours after vaccination. Nine patients required antihistamines for treatment. The median time to symptom resolution was 4 days. Nine patients underwent allergist-directed COVID-19 vaccine excipient skin testing, all of which were negative. Ten patients chose to receive their next mRNA COVID-19 vaccine dose, and four patients experienced recurrent delayed urticaria. Delayed systemic urticarial reactions after mRNA COVID-19 vaccination were not life-threatening, could be treated with antihistamines, and were not predicted with vaccine excipient skin testing. They were not a contraindication to subsequent vaccination, although patients should be counseled with regard to the possibility of recurrence.

摘要

随着针对 2019 年冠状病毒病(COVID-19)大流行的疫苗接种活动持续进行,人们对疫苗不良反应的担忧依然存在。虽然速发型过敏反应备受关注,但疫苗接种后可发生迟发性全身性荨麻疹反应。本研究旨在描述在信使 RNA(mRNA)COVID-19 疫苗接种后发生迟发性全身性荨麻疹反应的患者的临床表现、疫苗赋形剂皮肤试验结果和随后 COVID-19 疫苗接种的结果。这是一项回顾性病例系列研究,纳入了 2021 年 1 月 19 日至 2021 年 4 月 30 日期间在明尼苏达州罗切斯特市和佛罗里达州杰克逊维尔市的梅奥诊所就诊的 12 例患者,这些患者因 mRNA COVID-19 疫苗接种后发生迟发性全身性荨麻疹反应而接受评估。收集每位患者的人口统计学信息、医疗和过敏史、反应详细信息、疫苗赋形剂皮肤试验结果(如果进行了皮肤试验)以及随后接种疫苗的结果。患者的平均年龄为 52 岁,均为白人,9 例(75%)为女性。半数患者有药物过敏史,1 例有慢性自发性荨麻疹病史。7 例患者对辉瑞-BioNTech 疫苗有反应,5 例患者对 Moderna 疫苗有反应。7 例患者在接种疫苗后 8 至 24 小时出现症状。9 例患者需要抗组胺药治疗。症状缓解的中位时间为 4 天。9 例患者接受了过敏症专家指导的 COVID-19 疫苗赋形剂皮肤试验,结果均为阴性。10 例患者选择接种下一剂 mRNA COVID-19 疫苗,其中 4 例出现迟发性荨麻疹复发。mRNA COVID-19 疫苗接种后发生的迟发性全身性荨麻疹反应无生命危险,可用抗组胺药治疗,且疫苗赋形剂皮肤试验无法预测。这些反应不是随后接种疫苗的禁忌证,但应向患者说明复发的可能性。

相似文献

1
Delayed systemic urticarial reactions following mRNA COVID-19 vaccination.
Allergy Asthma Proc. 2022 Jan 1;43(1):40-43. doi: 10.2500/aap.2022.43.210101.
2
Utility and futility of skin testing to address concerns surrounding messenger RNA coronavirus disease 2019 vaccine reactions.
Ann Allergy Asthma Immunol. 2022 Feb;128(2):153-160. doi: 10.1016/j.anai.2021.11.006. Epub 2021 Nov 16.
3
Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series.
JAMA Dermatol. 2021 Jun 1;157(6):716-720. doi: 10.1001/jamadermatol.2021.1214.
4
Allergic reactions to coronavirus disease 2019 vaccines and addressing vaccine hesitancy: Northwell Health experience.
Ann Allergy Asthma Immunol. 2022 Feb;128(2):161-168.e1. doi: 10.1016/j.anai.2021.10.019. Epub 2021 Oct 24.
5
6
Case series of chronic spontaneous urticaria following COVID-19 vaccines: an unusual skin manifestation.
Eur J Clin Pharmacol. 2022 Dec;78(12):1959-1964. doi: 10.1007/s00228-022-03399-8. Epub 2022 Oct 18.
7
Monitored COVID-19 mRNA vaccine second doses for people with adverse reactions after the first dose.
Allergy Asthma Proc. 2022 Jan 1;43(1):37-39. doi: 10.2500/aap.2022.43.210100.
8
First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing.
J Allergy Clin Immunol Pract. 2021 Sep;9(9):3308-3320.e3. doi: 10.1016/j.jaip.2021.06.010. Epub 2021 Jun 22.
9
Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk.
JAMA Netw Open. 2021 Aug 2;4(8):e2122255. doi: 10.1001/jamanetworkopen.2021.22255.
10
Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age.
J Pediatr. 2021 Nov;238:26-32.e1. doi: 10.1016/j.jpeds.2021.07.044. Epub 2021 Jul 30.

引用本文的文献

2
Cutaneous Adverse Events Following COVID-19 Vaccination in Japan: A Questionnaire Survey.
Cureus. 2025 Mar 8;17(3):e80257. doi: 10.7759/cureus.80257. eCollection 2025 Mar.
3
Right Biceps Pseudo-Tumor from COVID-19 Vaccination.
Vaccines (Basel). 2024 Feb 3;12(2):160. doi: 10.3390/vaccines12020160.
5
Shoulder Pseudo-Tumor from COVID-19 Vaccine.
Vaccines (Basel). 2023 Apr 4;11(4):793. doi: 10.3390/vaccines11040793.
6
The complexities of allergic diseases continue to challenge the allergist-immunologist.
Allergy Asthma Proc. 2023 Mar 1;44(2):87-89. doi: 10.2500/aap.2023.44.230002.
7
Vaccine confidence among those living with allergy during the COVID pandemic (ACCORD): A scoping review.
J Allergy Clin Immunol Glob. 2023 May;2(2):100079. doi: 10.1016/j.jacig.2023.100079. Epub 2023 Feb 8.
8
Did the COVID-19 pandemic impact urticaria information-seeking behavior in China? A retrospective longitudinal study.
Front Public Health. 2023 Jan 19;11:1098066. doi: 10.3389/fpubh.2023.1098066. eCollection 2023.
9
COVID arm as a common cutaneous manifestation after mRNA-1273 vaccination: a systematic review.
BMC Infect Dis. 2023 Jan 6;23(1):7. doi: 10.1186/s12879-022-07973-4.

本文引用的文献

1
Cutaneous adverse reactions after COVID-19 vaccines in a cohort of 2740 Italian subjects: An observational study.
Dermatol Ther. 2021 Nov;34(6):e15153. doi: 10.1111/dth.15153. Epub 2021 Oct 13.
2
COVID-19 Vaccines and the Skin: The Landscape of Cutaneous Vaccine Reactions Worldwide.
Dermatol Clin. 2021 Oct;39(4):653-673. doi: 10.1016/j.det.2021.05.016. Epub 2021 May 31.
4
First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing.
J Allergy Clin Immunol Pract. 2021 Sep;9(9):3308-3320.e3. doi: 10.1016/j.jaip.2021.06.010. Epub 2021 Jun 22.
5
Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series.
JAMA Dermatol. 2021 Jun 1;157(6):716-720. doi: 10.1001/jamadermatol.2021.1214.
6
Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines.
J Allergy Clin Immunol. 2021 Jun;147(6):2075-2082.e2. doi: 10.1016/j.jaci.2021.04.002. Epub 2021 Apr 20.
7
Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases.
J Am Acad Dermatol. 2021 Jul;85(1):46-55. doi: 10.1016/j.jaad.2021.03.092. Epub 2021 Apr 7.
8
Polyethylene glycol and polysorbate skin testing in the evaluation of coronavirus disease 2019 vaccine reactions: Early report.
Ann Allergy Asthma Immunol. 2021 Jun;126(6):735-738. doi: 10.1016/j.anai.2021.03.012. Epub 2021 Mar 26.
9
Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2.
N Engl J Med. 2021 Apr 1;384(13):1273-1277. doi: 10.1056/NEJMc2102131. Epub 2021 Mar 3.
10
COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee.
World Allergy Organ J. 2021 Feb;14(2):100517. doi: 10.1016/j.waojou.2021.100517. Epub 2021 Feb 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验